Huang Xiaobo, Hu Wenjuan, Chen Lijun, Ma Liting, Yu Gengen, Chen Juanxia, Zhang Huifang, Cao Fan, Wang Huijie
Department of Respiratory and Critical Care Medicine, Second Clinical Medical College of NingXia Medical University (The First People's Hospital of Yinchuan), Yinchuan, Ningxia Province, China.
Lung Disease Department, Yulin Hospital of Traditional Chinese Medicine, Yulin, Shanxi Province, China.
Clin Exp Hypertens. 2025 Dec;47(1):2511056. doi: 10.1080/10641963.2025.2511056. Epub 2025 May 26.
This study explored miRNA-126 and HIF-1α levels in patients with OSAHS-related hypertension. To analyze the relationship between miRNA-126 and OSAHS-related hypertension and explore the pathogenic mechanisms of miRNA-126 and the HIF-1α pathway.
The 120 participants were assigned to four groups based on their apnea-hypopnea index (AHI) and the presence of hypertension: healthy control group, hypertension group, non-hypertensive OSAHS group, and OSAHS-related hypertension group, with 30 objects in each group. All subjects underwent overnight sleep monitoring and 24-hour (h) ambulatory blood pressure. Their blood samples were analyzed for the following parameters: triglycerides (TG), fasting blood glucose (GLU), total cholesterol (TC), HDL, uric acid (UA), and LDL, hypoxia-inducible factor-1 alpha (HIF-1α), VEGF, C-reactive protein (CRP), IL-6 and tumor necrosis factor alpha (TNF-α). The relative expression levels of miRNA-126 were assessed by RT-qPCR and Western blotting, and dual-luciferase reporter assays were conducted to verify the association between miR-126-3p and HIF1-α.
Results indicated that HIF-1α is a target gene of miRNA-126 and is negatively regulated by miRNA-126; Levels of miRNA-126 were significantly lower in OSAHS and hypertension patients relative to healthy controls, with the lowest levels observed in the OSAHS-related hypertension group( < .05). miRNA-126 levels were negatively correlated with HIF-1α, VEGF, TNF-α, CRP, IL-6, TG, TC, LDL, GLU and UA levels ( < .01), while it showed positive correlation with HDL level ( < .01).
The level of miRNA-126 in patients with OSAHS-related hypertension is lower than that in patients with OSAHS alone and those with hypertension alone.
本研究探讨阻塞性睡眠呼吸暂停低通气综合征（OSAHS）相关性高血压患者体内微小RNA-126（miRNA-126）和缺氧诱导因子-1α（HIF-1α）水平。分析miRNA-126与OSAHS相关性高血压之间的关系，探讨miRNA-126及HIF-1α信号通路的致病机制。
根据呼吸暂停低通气指数（AHI）及是否患有高血压，将120名参与者分为四组：健康对照组、高血压组、非高血压性OSAHS组和OSAHS相关性高血压组，每组30例。所有受试者均接受整夜睡眠监测及24小时动态血压监测。检测其血液样本中的以下参数：甘油三酯（TG）、空腹血糖（GLU）、总胆固醇（TC）、高密度脂蛋白（HDL）、尿酸（UA）、低密度脂蛋白（LDL）、缺氧诱导因子-1α（HIF-1α）、血管内皮生长因子（VEGF）、C反应蛋白（CRP）、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）。采用逆转录定量聚合酶链反应（RT-qPCR）和蛋白质免疫印迹法检测miRNA-126的相对表达水平，并进行双荧光素酶报告基因检测以验证miR-126-3p与HIF1-α之间的关联。
结果表明，HIF-1α是miRNA-126的靶基因，且受miRNA-126负调控；与健康对照组相比，OSAHS患者及高血压患者体内miRNA-126水平显著降低，其中OSAHS相关性高血压组水平最低（P＜0.05）。miRNA-126水平与HIF-1α、VEGF、TNF-α、CRP、IL-6、TG、TC、LDL、GLU及UA水平呈负相关（P＜0.01），与HDL水平呈正相关（P＜0.01）。
OSAHS相关性高血压患者体内miRNA-126水平低于单纯OSAHS患者及单纯高血压患者。
